BioCentury | Dec 31, 2020
Distillery Therapeutics

BRD4 as a DMD target

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy Inhibiting BRD4 and other BET proteins could treat Duchenne muscular dystrophy (DMD). Levels of BRD4 protein in paravertebral muscles were higher in four DMD patients than in two healthy volunteers....
BioCentury | Dec 31, 2020

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

Covaxx licenses COVID vaccine to Aurobindo Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) gained exclusive rights from the Covaxx unit of United Biomedical Inc. to develop and market UB-612 in India...
BioCentury | Nov 23, 2020

Cytokinetics evaluating path forward for heart disease treatment after Amgen ends partnership

Cytokinetics is assessing whether to commercialize omecamtiv mecarbil on its own or to seek a new partner after Amgen returned the heart failure treatment’s rights, ending a 2006 deal. President and CEO Robert Blum told a...
BioCentury | Nov 13, 2020
Product Development

Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients

Updated data from the Phase III GALACTIC-HF study of omecamtiv mecarbil show it may be particularly useful in a more severe subgroup of heart failure patients. The latest readout from Cytokinetics...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

Pivotal heart failure data 14 years in the making tripped up Cytokinetics and Amgen Thursday, leaving the former company looking ahead to 1H21 to complete enrollment for another Phase III study of omecamtiv mecarbil. Its next hope is the...
BioCentury | Oct 5, 2020

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

BMS is looking to diversify beyond its heavy reliance on its cancer portfolio through a $13.1 billion takeout of cardiovascular company MyoKardia. For MyoKardia Inc. (NASDAQ:MYOK), the $225 per share acquisition price is a 61%...
BioCentury | Sep 8, 2020
Product Development

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19

This is the second article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development...
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185) and then challenged with mouse-adapted SARS-CoV-2 had no detectable virus in the lungs and nose...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...
Items per page:
1 - 10 of 330